Ono Pharmaceutical, founded in 1717 and based in Osaka, develops and markets prescription medicines and had 4,206 consolidated employees in March 2026. Its cancer products include Opdivo, Kyprolis, Velexbru, Braftovi and Mektovi. Other injectables include Orencia for rheumatoid arthritis, Parsabiv for secondary hyperparathyroidism and Onoact for tachyarrhythmia.
Its oral products include Glactiv for type 2 diabetes, Ongentys for Parkinson's disease and Coralan for chronic heart failure. Onon treats bronchial asthma and allergic rhinitis, and Staybla is used for overactive bladder. Rivastach is a skin patch for Alzheimer's disease.
0
open positions at Ono Pharmaceutical
No live listings from Ono Pharmaceutical right now — browse all Tokyo software jobs instead.